<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02362503</url>
  </required_header>
  <id_info>
    <org_study_id>205888</org_study_id>
    <secondary_id>AI438-047</secondary_id>
    <secondary_id>2014-002111-41</secondary_id>
    <nct_id>NCT02362503</nct_id>
  </id_info>
  <brief_title>Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients</brief_title>
  <official_title>A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the BMS Attachment Inhibitor (BMS-663068)
      is effective in the treatment of heavily treatment experienced HIV-1 patients with multi-drug
      resistance.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 23, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Actual">August 18, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort</measure>
    <time_frame>Day 1 and Day 8</time_frame>
    <description>Plasma samples were collected for analysis of HIV-1 RNA. Mean change in log10 HIV-1 RNA from Day 1 was estimated using analysis of covariance (ANCOVA) with log10 HIV-1 RNA change from Day 1 at Day 8 as dependent variable, treatment (fostemsavir or placebo) as an independent variable, and Day 1 log10 HIV-1 RNA as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. The analysis was performed on Intent-to-Treat Exposed (ITT-E) Population which comprised of all randomized participants who received at least one dose of study treatment. Missing HIV-1 RNA values at Day 8 were imputed using (a) Day 1 Observation Carried Forward (D1OCF) for participants without a value during blinded treatment (i.e, imputing a zero change from Day 1) or (b) Last Observation Carried Forward (LOCF) for participants with an early value during blinded treatment before the Day 8 analysis visit window.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA Decreases From Day 1 That Exceed 0.5 log10 c/mL and 1.0 log10 c/mL at Day 8-Randomized Cohort</measure>
    <time_frame>Day 1 and Day 8</time_frame>
    <description>The percentage of participants in the Randomized Cohort with HIV-1 RNA decreases from Day 1 that exceed 0.5 log10 c/mL and 1.0 log10 c/mL at Day 8 was determined by comparing HIV-1 RNA Day 1 measurement of each participant to their Day 8 measurement. This was an ITT analysis that classified participants without HIV-1 RNA at Day 1 or Day 8 as failures. The percentage of responders along with 95% confidence interval based on Wilson score is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt;40 c/mL at Weeks 24 and 48-Randomized Cohort</measure>
    <time_frame>Weeks 24 and 48</time_frame>
    <description>The durability of response (that is, the number of participants achieving HIV-1 RNA &lt;40 c/mL) at Weeks 24 and 48 of open-label fostemsavir plus OBT in the Randomized Cohort was assessed using the Food and Drug Administration (FDA) snapshot algorithm in which participants without HIV-1 RNA at Weeks 24 and 48 or those who changed OBT due to lack of efficacy through Weeks 24 and 48 were counted as failures. The percentage of participants in the Randomized Cohort who achieved virologic success (HIV-1 RNA &lt;40 c/mL) at Weeks 24 and 48 is presented along with 95% Wilson confidence interval. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With On-treatment Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation (AELD)-Randomized Cohort</measure>
    <time_frame>Up to Week 48 analysis cut-off date</time_frame>
    <description>An SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or causes prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; an important medical event that may jeopardize the participant or require intervention. Number of participants with on-treatment SAEs and AEs leading to withdrawal of study treatment is presented. SAEs and AELDs were collected in Safety Population which comprised of all participants who received at least one dose of study treatment. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Toxicity Grade Increase in Clinical Chemistry Results to Grade 3-4 Relative to Baseline-Randomized Cohort</measure>
    <time_frame>Baseline and up to Week 48 analysis cut-off date</time_frame>
    <description>Laboratory toxicities were graded for severity according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading system: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening). Baseline is defined as the latest pre-dose assessment. The number of participants with clinical chemistry toxicity grade increase to Grade 3-4 at anytime post-Baseline relative to Baseline is presented. Only participants with data available at the specified time points were analyzed (represented by n=X in category titles). All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Toxicity Grade Increase in Hematology Results to Grade 3-4 Relative to Baseline-Randomized Cohort</measure>
    <time_frame>Baseline and up to Week 48 analysis cut-off date</time_frame>
    <description>Laboratory toxicities were graded for severity according to the DAIDS grading system: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening). Baseline is defined as the latest pre-dose assessment. The number of participants with hematology toxicity grade increase to Grade 3-4 at anytime post-Baseline relative to Baseline is presented. Only participants with data available at the specified time points were analyzed (represented by n=X in category titles). All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Centers for Disease Control (CDC) Class C Events-Randomized Cohort</measure>
    <time_frame>Up to Week 48 analysis cut-off date</time_frame>
    <description>Disease progression during open label fostemsavir plus OBT was assessed based on the occurrence of new AIDS defining events (CDC Class C events) or death. The number of participants with on-treatment CDC Class C AIDS events is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Day 1 in Cluster of Differentiation (CD) 4+ T-cell Count at Day 8-Randomized Cohort</measure>
    <time_frame>Day 1 and Day 8</time_frame>
    <description>CD4+ T- cell counts were assessed by flow cytometry. Mean change in CD4+ T- cell count from Day 1 at Day 8 was analyzed using one-way ANCOVA with change of CD4+ cell counts from Day 1 at Day 8 as the dependent variable, treatment (fostemsavir or placebo) as an in-dependent variable, and Day 1 CD4+ cell count as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. Missing CD4+ cell count values at Day 8 were imputed using (a) D1OCF for participants without a value during blinded treatment (i.e., imputing a zero change from Day 1), or (b) LOCF for participants with an early value during blinded treatment before the Day 8 analysis visit window.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+ T- Cell Count Percentage From Day 1 at Day 8-Randomized Cohort</measure>
    <time_frame>Day 1 and Day 8</time_frame>
    <description>CD4+ T- cell counts were assessed by flow cytometry. Mean change in CD4+ T- cell count percentage from Day 1 at Day 8 was analyzed using one-way ANCOVA with change of CD4+ cell count percentage from Day 1 at Day 8 as the dependent variable, treatment (fostemsavir or placebo) as an independent variable, and Day 1 CD4+ cell count percentage as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. Missing CD4+ cell count values at Day 8 were imputed using (a) D1OCF for participants without a value during blinded treatment (ie, imputing a zero change from Day 1), or (b) LOCF for participants with an early value during blinded treatment before the Day 8 analysis visit window.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in log10 HIV-1 RNA for Fostemsavir When Given With OBT Through Week 48-Randomized Cohort</measure>
    <time_frame>Baseline and up to Week 48</time_frame>
    <description>Blood samples were collected for the analysis of HIV-1 RNA. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles). All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4+ T- Cell Count Through Week 48-Randomized Cohort</measure>
    <time_frame>Baseline and up to Week 48</time_frame>
    <description>CD4+ T- cell counts were assessed by flow cytometry. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles). All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4+ T- Cell Count Percentage Through Week 48</measure>
    <time_frame>Baseline and up to Week 48</time_frame>
    <description>CD4+ T- cell counts were assessed by flow cytometry. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles). All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Viral Genotypic Substitution of Interest in the GP160 Domain as a Measure of Genotypic Resistance-Randomized Cohort</measure>
    <time_frame>Week 48</time_frame>
    <description>Plasma samples were collected for drug resistance testing. Participants with emergent viral genotypic substitutions of interest in GP160 domain was identified by next-generation sequencing (NGS) assay. Virologic failure (VF) Population comprised of all participants with available phenotypic and genotypic resistance data meeting at the time protocol defined virologic failure (PDVF) was met. Criteria for PDVF was a) Confirmed, or last available prior to discontinuation, HIV-1 RNA &gt;=400 c/mL at any time after prior confirmed suppression to &lt;400 c/mL prior to Week 24 or Confirmed, or last available prior to discontinuation, &gt;1 log10 c/mL increase in HIV-1 RNA at any time above nadir level where nadir is &gt;=40 c/mL prior to Week 24. b) Confirmed, or last available prior to discontinuation, HIV-1 RNA &gt;=400 c/mL at or after Week 24. All participants received fostemsavir during open-label period irrespective of original randomization; hence, combined totals for Randomized Cohort is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Indicated Fold Change Ratio (FCR) Using the Monogram PhenoSense Entry Assay-Randomized Cohort</measure>
    <time_frame>Week 48</time_frame>
    <description>The phenotypic resistance to a drug is defined in terms of a fold change (FC) in IC50s, ie, the ratio of the 50% inhibitory concentration (IC50) of the clinical isolate to the IC50 of a reference strain (wild type control). FCR was calculated as FC at PDVF divided by Baseline FC. The number of participants with the indicated change (ratio) in the two values at the time of PDVF is presented. FCR&lt;1 indicates that FC is smaller on-treatment than at Baseline. FCR &gt;3 indicates that on-treatment FC is 3 times greater than it was at Baseline. All the participants received fostemsavir during open-label period irrespective of the original arms to which they were randomized; hence, combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">371</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A1: BMS-663068</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: BMS-663068 600 mg tablets orally twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1: Placebo + BMS-663068</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phase 1: Placebo twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-663068</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-663068</intervention_name>
    <description>BMS-663068</description>
    <arm_group_label>A1: BMS-663068</arm_group_label>
    <arm_group_label>B1: Placebo + BMS-663068</arm_group_label>
    <arm_group_label>BMS-663068</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>B1: Placebo + BMS-663068</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and non-pregnant women with chronic HIV-1 infection

          -  Antiretroviral-experienced with documented historical or baseline resistance,
             intolerability, and/or contraindications to antiretrovirals in at least three classes

          -  Failing current antiretroviral regimen with a confirmed plasma HIV-1 RNA ≥ 400 c/mL
             (first value from Investigator, second from Screening labs)

          -  Must have ≤ 2 classes with at least 1 but no more than 2 fully-active antiretrovirals
             remaining which can be effectively combined to form a viable new regimen, based on
             current and/or documented historical resistance testing and tolerability and safety

          -  Able to receive ≥ 1 fully active approved antiretroviral as part of the OBT from Day 9
             onwards in the Randomized Cohort

          -  Subjects without any remaining fully active approved antiretroviral may be enrolled in
             the Non-Randomized Cohort

        Exclusion Criteria:

          -  Chronic untreated Hepatitis B virus (HBV) (however, patients with chronic treated HBV
             are eligible)

          -  HIV-2 infection

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 7 x ULN

          -  Alkaline Phosphatase &gt; 5 x ULN

          -  Bilirubin ≥ 1.5 x Upper limit of normal (ULN) (unless subject is currently on
             atazanavir and has predominantly unconjugated hyperbilirubinemia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oakland Park</city>
        <state>Florida</state>
        <zip>33306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1426ABP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1405CKC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <state>Córdova</state>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <state>Córdova</state>
        <zip>X5000JJS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1141ACG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1155ADP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1202ABB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Antwerpen</city>
        <zip>2000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>80240-280</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13015-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>01416-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>04040-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>04121-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ribeirao Preto</city>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21040-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salvador</city>
        <zip>40110-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 5B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <zip>V6H3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago Centro</city>
        <state>Región Metro De Santiago</state>
        <zip>8360159</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Región Metro De Santiago</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <zip>7500520</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <zip>8330074</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Temuco</city>
        <zip>4781151</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cali, Valle Del Cauca</city>
        <zip>760032</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bordeaux cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris Cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dortmund</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>16121</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>Dublin 7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad de México</city>
        <state>Estado De México</state>
        <zip>﻿03100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad de Mexico</city>
        <zip>6700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Distrito Federal</city>
        <zip>06470</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Distrito Federal</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iquitos</city>
        <state>Loreto</state>
        <zip>Iqui 01</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>11</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>14</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>1</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima 31</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Szczecin</city>
        <zip>70-376</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-201</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-149</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1069-166</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lisbon</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Juan</city>
        <zip>909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>72205</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Irkutsk</city>
        <zip>664035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krasnodar</city>
        <zip>350015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Port Elizabeth</city>
        <state>Eastern Cape</state>
        <zip>6001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Benoni</city>
        <state>Gauteng</state>
        <zip>1500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dundee</city>
        <state>KwaZulu- Natal</state>
        <zip>3000</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Observatory</city>
        <state>Western Province</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durban</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Badalona, Barcelona</city>
        <zip>8916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seville, Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leicestershire</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>February 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2015</study_first_posted>
  <results_first_submitted>August 2, 2018</results_first_submitted>
  <results_first_submitted_qc>August 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2018</results_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a 2 cohort Phase 3 study conducted in heavily treatment experienced (HTE) participants infected with multi-drug resistant human immunodeficiency virus (HIV)-1. Based on the number of fully active and available antiretroviral drug classes at Screening, participants were assigned to either Randomized Cohort or Non-randomized Cohort.</recruitment_details>
      <pre_assignment_details>A total of 731 participants were screened, of which 371 were included in either Randomized Cohort (fostemsavir or placebo) or Non-randomized Cohort (fostemsavir) and received at least one dose of study treatment. The study was conducted in 24 countries. The results presented are based on the Week 48 Interim Analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Randomized Cohort-Placebo</title>
          <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received placebo twice daily (BID) along with their currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants received fostemsavir 600 mg BID with an optimized background therapy (OBT).</description>
        </group>
        <group group_id="P2">
          <title>Randomized Cohort-fostemsavir 600 mg BID</title>
          <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received fostemsavir 600 milligram (mg) BID along with currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants continued to receive fostemsavir 600 mg BID with an OBT.</description>
        </group>
        <group group_id="P3">
          <title>Non-randomized Cohort-fostemsavir 600 mg BID</title>
          <description>HTE HIV-1 infected participants with no remaining classes of fully active antiretroviral that could be combined in a new drug regimen were included in the Non-randomized Cohort. Participants received fostemsavir 600 mg BID in combination with OBT.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind Period-Up to 8 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="203"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="198"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open Label Period-Up to Atleast 96 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="198">Subject withdrawn due to progression of disease died during study due to squamous cell carcinoma.</participants>
                <participants group_id="P3" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="198"/>
                <participants group_id="P3" count="99"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression of disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing at the time of analysis</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="160"/>
                <participants group_id="P3" count="67"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Randomized Cohort-Placebo</title>
          <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received placebo twice daily (BID) along with their currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants received fostemsavir 600 mg BID with an optimized background therapy (OBT).</description>
        </group>
        <group group_id="B2">
          <title>Randomized Cohort-fostemsavir 600 mg BID</title>
          <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received fostemsavir 600 milligram (mg) BID along with currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants continued to receive fostemsavir 600 mg BID with an OBT.</description>
        </group>
        <group group_id="B3">
          <title>Non-randomized Cohort-fostemsavir 600 mg BID</title>
          <description>HTE HIV-1 infected participants with no remaining classes of fully active antiretroviral that could be combined in a new drug regimen were included in the Non-randomized Cohort. Participants received fostemsavir 600 mg BID in combination with OBT.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
            <count group_id="B2" value="203"/>
            <count group_id="B3" value="99"/>
            <count group_id="B4" value="371"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.0" spread="11.02"/>
                    <measurement group_id="B2" value="45.2" spread="12.72"/>
                    <measurement group_id="B3" value="48.1" spread="11.53"/>
                    <measurement group_id="B4" value="45.6" spread="12.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race customized</title>
              <category_list>
                <category>
                  <title>African American/African Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or other Pacific islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="257"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mixed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mestizo</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>North African</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mulatto</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Brown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White and African descent</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort</title>
        <description>Plasma samples were collected for analysis of HIV-1 RNA. Mean change in log10 HIV-1 RNA from Day 1 was estimated using analysis of covariance (ANCOVA) with log10 HIV-1 RNA change from Day 1 at Day 8 as dependent variable, treatment (fostemsavir or placebo) as an independent variable, and Day 1 log10 HIV-1 RNA as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. The analysis was performed on Intent-to-Treat Exposed (ITT-E) Population which comprised of all randomized participants who received at least one dose of study treatment. Missing HIV-1 RNA values at Day 8 were imputed using (a) Day 1 Observation Carried Forward (D1OCF) for participants without a value during blinded treatment (i.e, imputing a zero change from Day 1) or (b) Last Observation Carried Forward (LOCF) for participants with an early value during blinded treatment before the Day 8 analysis visit window.</description>
        <time_frame>Day 1 and Day 8</time_frame>
        <population>ITT-E Population. Participants with missing Day 1 HIV-1 RNA values were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Cohort-Placebo</title>
            <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received placebo twice daily (BID) along with their currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants received fostemsavir 600 mg BID with an optimized background therapy (OBT).</description>
          </group>
          <group group_id="O2">
            <title>Randomized Cohort-fostemsavir 600 mg BID</title>
            <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received fostemsavir 600 milligram (mg) BID along with currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants continued to receive fostemsavir 600 mg BID with an OBT.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort</title>
          <description>Plasma samples were collected for analysis of HIV-1 RNA. Mean change in log10 HIV-1 RNA from Day 1 was estimated using analysis of covariance (ANCOVA) with log10 HIV-1 RNA change from Day 1 at Day 8 as dependent variable, treatment (fostemsavir or placebo) as an independent variable, and Day 1 log10 HIV-1 RNA as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. The analysis was performed on Intent-to-Treat Exposed (ITT-E) Population which comprised of all randomized participants who received at least one dose of study treatment. Missing HIV-1 RNA values at Day 8 were imputed using (a) Day 1 Observation Carried Forward (D1OCF) for participants without a value during blinded treatment (i.e, imputing a zero change from Day 1) or (b) Last Observation Carried Forward (LOCF) for participants with an early value during blinded treatment before the Day 8 analysis visit window.</description>
          <population>ITT-E Population. Participants with missing Day 1 HIV-1 RNA values were not analyzed.</population>
          <units>Log10 copies per milliliter (c/mL)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.166" lower_limit="-0.326" upper_limit="-0.007"/>
                    <measurement group_id="O2" value="-0.791" lower_limit="-0.885" upper_limit="-0.698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Hypothesis test:µfostemsavir=µPlacebo where µ is a common intercept.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.625</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.810</ci_lower_limit>
            <ci_upper_limit>-0.441</ci_upper_limit>
            <estimate_desc>Difference in covariate-adjusted least squares means between treatment groups (Fostemsavir 600 mg BID-Placebo) is presented.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA Decreases From Day 1 That Exceed 0.5 log10 c/mL and 1.0 log10 c/mL at Day 8-Randomized Cohort</title>
        <description>The percentage of participants in the Randomized Cohort with HIV-1 RNA decreases from Day 1 that exceed 0.5 log10 c/mL and 1.0 log10 c/mL at Day 8 was determined by comparing HIV-1 RNA Day 1 measurement of each participant to their Day 8 measurement. This was an ITT analysis that classified participants without HIV-1 RNA at Day 1 or Day 8 as failures. The percentage of responders along with 95% confidence interval based on Wilson score is presented.</description>
        <time_frame>Day 1 and Day 8</time_frame>
        <population>ITT-E Population</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Cohort-Placebo</title>
            <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received placebo twice daily (BID) along with their currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants received fostemsavir 600 mg BID with an optimized background therapy (OBT).</description>
          </group>
          <group group_id="O2">
            <title>Randomized Cohort-fostemsavir 600 mg BID</title>
            <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received fostemsavir 600 milligram (mg) BID along with currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants continued to receive fostemsavir 600 mg BID with an OBT.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA Decreases From Day 1 That Exceed 0.5 log10 c/mL and 1.0 log10 c/mL at Day 8-Randomized Cohort</title>
          <description>The percentage of participants in the Randomized Cohort with HIV-1 RNA decreases from Day 1 that exceed 0.5 log10 c/mL and 1.0 log10 c/mL at Day 8 was determined by comparing HIV-1 RNA Day 1 measurement of each participant to their Day 8 measurement. This was an ITT analysis that classified participants without HIV-1 RNA at Day 1 or Day 8 as failures. The percentage of responders along with 95% confidence interval based on Wilson score is presented.</description>
          <population>ITT-E Population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;0.5 log10 c/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.84" lower_limit="11.35" upper_limit="29.61"/>
                    <measurement group_id="O2" value="64.53" lower_limit="57.74" upper_limit="70.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.0 log10 c/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.14" lower_limit="5.00" upper_limit="19.49"/>
                    <measurement group_id="O2" value="45.81" lower_limit="39.10" upper_limit="52.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>45.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>32.95</ci_lower_limit>
            <ci_upper_limit>55.45</ci_upper_limit>
            <estimate_desc>Difference between treatment groups (fostemsavir 600 mg BID-Placebo) and 95% confidence interval using Newcombe method is presented for &gt;0.5 log10 c/mL.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>35.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24.16</ci_lower_limit>
            <ci_upper_limit>44.25</ci_upper_limit>
            <estimate_desc>Difference between treatment groups (fostemsavir 600 mg BID-Placebo) and 95% confidence interval using Newcombe method is presented for &gt;1.0 log10 c/mL.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt;40 c/mL at Weeks 24 and 48-Randomized Cohort</title>
        <description>The durability of response (that is, the number of participants achieving HIV-1 RNA &lt;40 c/mL) at Weeks 24 and 48 of open-label fostemsavir plus OBT in the Randomized Cohort was assessed using the Food and Drug Administration (FDA) snapshot algorithm in which participants without HIV-1 RNA at Weeks 24 and 48 or those who changed OBT due to lack of efficacy through Weeks 24 and 48 were counted as failures. The percentage of participants in the Randomized Cohort who achieved virologic success (HIV-1 RNA &lt;40 c/mL) at Weeks 24 and 48 is presented along with 95% Wilson confidence interval. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
        <time_frame>Weeks 24 and 48</time_frame>
        <population>ITT-E Population</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Cohort</title>
            <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants were randomized to receive fostemsavir 600 mg BID or placebo along with their current failing antiretroviral regimen during the double-blind period for 8 days. During the open-label period, all participants received open-label fostemsavir 600 mg BID in combination with OBT for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA &lt;40 c/mL at Weeks 24 and 48-Randomized Cohort</title>
          <description>The durability of response (that is, the number of participants achieving HIV-1 RNA &lt;40 c/mL) at Weeks 24 and 48 of open-label fostemsavir plus OBT in the Randomized Cohort was assessed using the Food and Drug Administration (FDA) snapshot algorithm in which participants without HIV-1 RNA at Weeks 24 and 48 or those who changed OBT due to lack of efficacy through Weeks 24 and 48 were counted as failures. The percentage of participants in the Randomized Cohort who achieved virologic success (HIV-1 RNA &lt;40 c/mL) at Weeks 24 and 48 is presented along with 95% Wilson confidence interval. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
          <population>ITT-E Population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="47.0" upper_limit="58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="47.7" upper_limit="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With On-treatment Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation (AELD)-Randomized Cohort</title>
        <description>An SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or causes prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; an important medical event that may jeopardize the participant or require intervention. Number of participants with on-treatment SAEs and AEs leading to withdrawal of study treatment is presented. SAEs and AELDs were collected in Safety Population which comprised of all participants who received at least one dose of study treatment. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
        <time_frame>Up to Week 48 analysis cut-off date</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Cohort</title>
            <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants were randomized to receive fostemsavir 600 mg BID or placebo along with their current failing antiretroviral regimen during the double-blind period for 8 days. During the open-label period, all participants received open-label fostemsavir 600 mg BID in combination with OBT for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With On-treatment Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation (AELD)-Randomized Cohort</title>
          <description>An SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or causes prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; an important medical event that may jeopardize the participant or require intervention. Number of participants with on-treatment SAEs and AEs leading to withdrawal of study treatment is presented. SAEs and AELDs were collected in Safety Population which comprised of all participants who received at least one dose of study treatment. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AELD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Toxicity Grade Increase in Clinical Chemistry Results to Grade 3-4 Relative to Baseline-Randomized Cohort</title>
        <description>Laboratory toxicities were graded for severity according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading system: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening). Baseline is defined as the latest pre-dose assessment. The number of participants with clinical chemistry toxicity grade increase to Grade 3-4 at anytime post-Baseline relative to Baseline is presented. Only participants with data available at the specified time points were analyzed (represented by n=X in category titles). All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
        <time_frame>Baseline and up to Week 48 analysis cut-off date</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Cohort</title>
            <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants were randomized to receive fostemsavir 600 mg BID or placebo along with their current failing antiretroviral regimen during the double-blind period for 8 days. During the open-label period, all participants received open-label fostemsavir 600 mg BID in combination with OBT for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Toxicity Grade Increase in Clinical Chemistry Results to Grade 3-4 Relative to Baseline-Randomized Cohort</title>
          <description>Laboratory toxicities were graded for severity according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading system: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening). Baseline is defined as the latest pre-dose assessment. The number of participants with clinical chemistry toxicity grade increase to Grade 3-4 at anytime post-Baseline relative to Baseline is presented. Only participants with data available at the specified time points were analyzed (represented by n=X in category titles). All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin; n=268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase; n=268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine aminotransferase; n=268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase; n=268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase; n=268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate; n=268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin; n=268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin; n=268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium; n=268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol; n=221</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="221"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine kinase; n=268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; n=268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estimated creatinine clearance; n=268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose/hyperglycemia; n=267</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="267"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose/hypoglycemia; n=267</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="267"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium/hyperkalemia; n=268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium/hypokalemia; n=268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low density lipoprotein (LDL) cholesterol; n=216</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase; n=268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium/hypernatremia; n=268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium/hyponatremia; n=268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides; n=221</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="221"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urate; n=268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Toxicity Grade Increase in Hematology Results to Grade 3-4 Relative to Baseline-Randomized Cohort</title>
        <description>Laboratory toxicities were graded for severity according to the DAIDS grading system: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening). Baseline is defined as the latest pre-dose assessment. The number of participants with hematology toxicity grade increase to Grade 3-4 at anytime post-Baseline relative to Baseline is presented. Only participants with data available at the specified time points were analyzed (represented by n=X in category titles). All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
        <time_frame>Baseline and up to Week 48 analysis cut-off date</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Cohort</title>
            <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants were randomized to receive fostemsavir 600 mg BID or placebo along with their current failing antiretroviral regimen during the double-blind period for 8 days. During the open-label period, all participants received open-label fostemsavir 600 mg BID in combination with OBT for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Toxicity Grade Increase in Hematology Results to Grade 3-4 Relative to Baseline-Randomized Cohort</title>
          <description>Laboratory toxicities were graded for severity according to the DAIDS grading system: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening). Baseline is defined as the latest pre-dose assessment. The number of participants with hematology toxicity grade increase to Grade 3-4 at anytime post-Baseline relative to Baseline is presented. Only participants with data available at the specified time points were analyzed (represented by n=X in category titles). All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin; n=268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils; n=268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets; n=267</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="267"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes; n=268</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Centers for Disease Control (CDC) Class C Events-Randomized Cohort</title>
        <description>Disease progression during open label fostemsavir plus OBT was assessed based on the occurrence of new AIDS defining events (CDC Class C events) or death. The number of participants with on-treatment CDC Class C AIDS events is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
        <time_frame>Up to Week 48 analysis cut-off date</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Cohort</title>
            <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants were randomized to receive fostemsavir 600 mg BID or placebo along with their current failing antiretroviral regimen during the double-blind period for 8 days. During the open-label period, all participants received open-label fostemsavir 600 mg BID in combination with OBT for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Centers for Disease Control (CDC) Class C Events-Randomized Cohort</title>
          <description>Disease progression during open label fostemsavir plus OBT was assessed based on the occurrence of new AIDS defining events (CDC Class C events) or death. The number of participants with on-treatment CDC Class C AIDS events is presented. All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Day 1 in Cluster of Differentiation (CD) 4+ T-cell Count at Day 8-Randomized Cohort</title>
        <description>CD4+ T- cell counts were assessed by flow cytometry. Mean change in CD4+ T- cell count from Day 1 at Day 8 was analyzed using one-way ANCOVA with change of CD4+ cell counts from Day 1 at Day 8 as the dependent variable, treatment (fostemsavir or placebo) as an in-dependent variable, and Day 1 CD4+ cell count as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. Missing CD4+ cell count values at Day 8 were imputed using (a) D1OCF for participants without a value during blinded treatment (i.e., imputing a zero change from Day 1), or (b) LOCF for participants with an early value during blinded treatment before the Day 8 analysis visit window.</description>
        <time_frame>Day 1 and Day 8</time_frame>
        <population>ITT-E Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Cohort-Placebo</title>
            <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received placebo twice daily (BID) along with their currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants received fostemsavir 600 mg BID with an optimized background therapy (OBT).</description>
          </group>
          <group group_id="O2">
            <title>Randomized Cohort-fostemsavir 600 mg BID</title>
            <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received fostemsavir 600 milligram (mg) BID along with currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants continued to receive fostemsavir 600 mg BID with an OBT.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Day 1 in Cluster of Differentiation (CD) 4+ T-cell Count at Day 8-Randomized Cohort</title>
          <description>CD4+ T- cell counts were assessed by flow cytometry. Mean change in CD4+ T- cell count from Day 1 at Day 8 was analyzed using one-way ANCOVA with change of CD4+ cell counts from Day 1 at Day 8 as the dependent variable, treatment (fostemsavir or placebo) as an in-dependent variable, and Day 1 CD4+ cell count as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. Missing CD4+ cell count values at Day 8 were imputed using (a) D1OCF for participants without a value during blinded treatment (i.e., imputing a zero change from Day 1), or (b) LOCF for participants with an early value during blinded treatment before the Day 8 analysis visit window.</description>
          <population>ITT-E Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Cells per cubic millimeter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" lower_limit="4.7" upper_limit="33.0"/>
                    <measurement group_id="O2" value="18.5" lower_limit="10.1" upper_limit="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.8</ci_lower_limit>
            <ci_upper_limit>16.0</ci_upper_limit>
            <estimate_desc>Difference in covariate-adjusted least squares means between treatment groups (Fostemsavir 600 mg BID-Placebo) is presented.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4+ T- Cell Count Percentage From Day 1 at Day 8-Randomized Cohort</title>
        <description>CD4+ T- cell counts were assessed by flow cytometry. Mean change in CD4+ T- cell count percentage from Day 1 at Day 8 was analyzed using one-way ANCOVA with change of CD4+ cell count percentage from Day 1 at Day 8 as the dependent variable, treatment (fostemsavir or placebo) as an independent variable, and Day 1 CD4+ cell count percentage as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. Missing CD4+ cell count values at Day 8 were imputed using (a) D1OCF for participants without a value during blinded treatment (ie, imputing a zero change from Day 1), or (b) LOCF for participants with an early value during blinded treatment before the Day 8 analysis visit window.</description>
        <time_frame>Day 1 and Day 8</time_frame>
        <population>ITT-E Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Cohort-Placebo</title>
            <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received placebo twice daily (BID) along with their currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants received fostemsavir 600 mg BID with an optimized background therapy (OBT).</description>
          </group>
          <group group_id="O2">
            <title>Randomized Cohort-fostemsavir 600 mg BID</title>
            <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants received fostemsavir 600 milligram (mg) BID along with currently failing antiretroviral regimen for 8 days during the randomized, double-blind period. During the open-label period, all participants continued to receive fostemsavir 600 mg BID with an OBT.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4+ T- Cell Count Percentage From Day 1 at Day 8-Randomized Cohort</title>
          <description>CD4+ T- cell counts were assessed by flow cytometry. Mean change in CD4+ T- cell count percentage from Day 1 at Day 8 was analyzed using one-way ANCOVA with change of CD4+ cell count percentage from Day 1 at Day 8 as the dependent variable, treatment (fostemsavir or placebo) as an independent variable, and Day 1 CD4+ cell count percentage as a continuous covariate. Change from Day 1 was calculated as value at Day 8 minus value at Day 1. Missing CD4+ cell count values at Day 8 were imputed using (a) D1OCF for participants without a value during blinded treatment (ie, imputing a zero change from Day 1), or (b) LOCF for participants with an early value during blinded treatment before the Day 8 analysis visit window.</description>
          <population>ITT-E Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Percentage of CD4+T- cells</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.243" lower_limit="-0.216" upper_limit="0.703"/>
                    <measurement group_id="O2" value="0.860" lower_limit="0.588" upper_limit="1.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.617</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.082</ci_lower_limit>
            <ci_upper_limit>1.151</ci_upper_limit>
            <estimate_desc>Difference in covariate-adjusted least squares means between treatment groups (Fostemsavir 600 mg BID-Placebo) is presented.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in log10 HIV-1 RNA for Fostemsavir When Given With OBT Through Week 48-Randomized Cohort</title>
        <description>Blood samples were collected for the analysis of HIV-1 RNA. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles). All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
        <time_frame>Baseline and up to Week 48</time_frame>
        <population>ITT-E Population</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Cohort</title>
            <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants were randomized to receive fostemsavir 600 mg BID or placebo along with their current failing antiretroviral regimen during the double-blind period for 8 days. During the open-label period, all participants received open-label fostemsavir 600 mg BID in combination with OBT for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in log10 HIV-1 RNA for Fostemsavir When Given With OBT Through Week 48-Randomized Cohort</title>
          <description>Blood samples were collected for the analysis of HIV-1 RNA. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles). All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
          <population>ITT-E Population</population>
          <units>Log10 c/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8; n=262</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="262"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.656" spread="0.7536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4; n=262</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="262"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.051" spread="1.0717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8; n=256</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.207" spread="1.1416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12; n=248</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.237" spread="1.2105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16; n=249</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.277" spread="1.2834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24; n=246</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.297" spread="1.2788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36; n=238</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="238"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.332" spread="1.2265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48; n=233</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="233"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.324" spread="1.2876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4+ T- Cell Count Through Week 48-Randomized Cohort</title>
        <description>CD4+ T- cell counts were assessed by flow cytometry. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles). All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
        <time_frame>Baseline and up to Week 48</time_frame>
        <population>ITT-E Population</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Cohort</title>
            <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants were randomized to receive fostemsavir 600 mg BID or placebo along with their current failing antiretroviral regimen during the double-blind period for 8 days. During the open-label period, all participants received open-label fostemsavir 600 mg BID in combination with OBT for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4+ T- Cell Count Through Week 48-Randomized Cohort</title>
          <description>CD4+ T- cell counts were assessed by flow cytometry. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles). All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
          <population>ITT-E Population</population>
          <units>Cells per cubic millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8; n=255</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" spread="60.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4; n=259</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9" spread="131.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8; n=254</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" spread="113.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12; n=249</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.0" spread="123.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16; n=245</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="245"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.1" spread="107.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24; n=247</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.4" spread="112.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36; n=234</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.7" spread="119.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48; n=228</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.9" spread="135.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4+ T- Cell Count Percentage Through Week 48</title>
        <description>CD4+ T- cell counts were assessed by flow cytometry. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles). All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
        <time_frame>Baseline and up to Week 48</time_frame>
        <population>ITT-E Population</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Cohort</title>
            <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants were randomized to receive fostemsavir 600 mg or placebo along with their current failing antiretroviral regimen during the double-blind period for 8 days. During the open-label period, all participants received open-label fostemsavir 600 mg BID in combination with OBT for at least 96 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4+ T- Cell Count Percentage Through Week 48</title>
          <description>CD4+ T- cell counts were assessed by flow cytometry. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as the value at post-dose visit minus the value at Baseline. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles). All the participants received fostemsavir during the open-label period irrespective of the original arms to which they were randomized; hence, the combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
          <population>ITT-E Population</population>
          <units>Percentage of CD4+ T- cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8; n=255</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="1.970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4; n=259</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" spread="4.643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8; n=254</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" spread="4.392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12; n=249</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="4.945"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16; n=245</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="245"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.51" spread="4.979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24; n=247</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" spread="4.828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36; n=234</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.06" spread="5.256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48; n=228</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.51" spread="5.531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Viral Genotypic Substitution of Interest in the GP160 Domain as a Measure of Genotypic Resistance-Randomized Cohort</title>
        <description>Plasma samples were collected for drug resistance testing. Participants with emergent viral genotypic substitutions of interest in GP160 domain was identified by next-generation sequencing (NGS) assay. Virologic failure (VF) Population comprised of all participants with available phenotypic and genotypic resistance data meeting at the time protocol defined virologic failure (PDVF) was met. Criteria for PDVF was a) Confirmed, or last available prior to discontinuation, HIV-1 RNA &gt;=400 c/mL at any time after prior confirmed suppression to &lt;400 c/mL prior to Week 24 or Confirmed, or last available prior to discontinuation, &gt;1 log10 c/mL increase in HIV-1 RNA at any time above nadir level where nadir is &gt;=40 c/mL prior to Week 24. b) Confirmed, or last available prior to discontinuation, HIV-1 RNA &gt;=400 c/mL at or after Week 24. All participants received fostemsavir during open-label period irrespective of original randomization; hence, combined totals for Randomized Cohort is presented.</description>
        <time_frame>Week 48</time_frame>
        <population>VF Population</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Cohort</title>
            <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants were randomized to receive fostemsavir 600 mg BID or placebo along with their current failing antiretroviral regimen during the double-blind period for 8 days. During the open-label period, all participants received open-label fostemsavir 600 mg BID in combination with OBT for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Viral Genotypic Substitution of Interest in the GP160 Domain as a Measure of Genotypic Resistance-Randomized Cohort</title>
          <description>Plasma samples were collected for drug resistance testing. Participants with emergent viral genotypic substitutions of interest in GP160 domain was identified by next-generation sequencing (NGS) assay. Virologic failure (VF) Population comprised of all participants with available phenotypic and genotypic resistance data meeting at the time protocol defined virologic failure (PDVF) was met. Criteria for PDVF was a) Confirmed, or last available prior to discontinuation, HIV-1 RNA &gt;=400 c/mL at any time after prior confirmed suppression to &lt;400 c/mL prior to Week 24 or Confirmed, or last available prior to discontinuation, &gt;1 log10 c/mL increase in HIV-1 RNA at any time above nadir level where nadir is &gt;=40 c/mL prior to Week 24. b) Confirmed, or last available prior to discontinuation, HIV-1 RNA &gt;=400 c/mL at or after Week 24. All participants received fostemsavir during open-label period irrespective of original randomization; hence, combined totals for Randomized Cohort is presented.</description>
          <population>VF Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Indicated Fold Change Ratio (FCR) Using the Monogram PhenoSense Entry Assay-Randomized Cohort</title>
        <description>The phenotypic resistance to a drug is defined in terms of a fold change (FC) in IC50s, ie, the ratio of the 50% inhibitory concentration (IC50) of the clinical isolate to the IC50 of a reference strain (wild type control). FCR was calculated as FC at PDVF divided by Baseline FC. The number of participants with the indicated change (ratio) in the two values at the time of PDVF is presented. FCR&lt;1 indicates that FC is smaller on-treatment than at Baseline. FCR &gt;3 indicates that on-treatment FC is 3 times greater than it was at Baseline. All the participants received fostemsavir during open-label period irrespective of the original arms to which they were randomized; hence, combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
        <time_frame>Week 48</time_frame>
        <population>VF Population. Only participants available at the specified time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Cohort</title>
            <description>HTE HIV-1 infected participants with &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen were included in the Randomized Cohort. Participants were randomized to receive fostemsavir 600 mg BID or placebo along with their current failing antiretroviral regimen during the double-blind period for 8 days. During the open-label period, all participants received open-label fostemsavir 600 mg BID in combination with OBT for at least 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Indicated Fold Change Ratio (FCR) Using the Monogram PhenoSense Entry Assay-Randomized Cohort</title>
          <description>The phenotypic resistance to a drug is defined in terms of a fold change (FC) in IC50s, ie, the ratio of the 50% inhibitory concentration (IC50) of the clinical isolate to the IC50 of a reference strain (wild type control). FCR was calculated as FC at PDVF divided by Baseline FC. The number of participants with the indicated change (ratio) in the two values at the time of PDVF is presented. FCR&lt;1 indicates that FC is smaller on-treatment than at Baseline. FCR &gt;3 indicates that on-treatment FC is 3 times greater than it was at Baseline. All the participants received fostemsavir during open-label period irrespective of the original arms to which they were randomized; hence, combined totals for Randomized Cohort is presented as pre-specified in protocol and reporting and analysis plan.</description>
          <population>VF Population. Only participants available at the specified time point were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1 to 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;3 to 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 to 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;100 to 3000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;3000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On-treatment non-SAEs and SAEs were collected from the start of study treatment until the Week 48 data cut-off date. The data presented for Randomized Cohort-Placebo and Randomized Cohort-fostemsavir 600 mg BID represent safety events during the double-blind period (Up to Day 8). The safety data presented in the Randomized Cohort-Total, Non-Randomized Cohort-fostemsavir 600 mg BID and Fostemsavir Total columns represent safety events during fostemsavir dosing until the Week 48 data cut-off date.</time_frame>
      <desc>Non-SAEs and SAEs were collected in the Safety Population which comprised of all participants who received at least one dose of study treatment. One participant was excluded from the Total fostemsavir population as the participant took only placebo and had discontinued during the double-blind period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Randomized Cohort-Placebo</title>
          <description>This reporting group includes HTE HIV-1 infected participants who were assigned to the Randomized Cohort and randomized to placebo twice daily (BID) along with their currently failing antiretroviral regimen for the double-blind period. During the open-label period, all participants received fostemsavir 600 mg BID and an optimized background therapy (OBT). Randomized Cohort participants are assigned based on their screening status of having &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen. The data reported are safety events during the 8-day double-blind period.</description>
        </group>
        <group group_id="E2">
          <title>Randomized Cohort-fostemsavir 600 mg BID</title>
          <description>This reporting group includes HTE HIV-1 infected participants who were assigned to the Randomized Cohort and randomized to fostemsavir 600 mg BID along with their currently failing antiretroviral regimen for the double-blind period. During the open-label period, all participants received fostemsavir 600 mg BID and OBT. Randomized Cohort participants are assigned based on their screening status of having &lt;=2 classes of antiretrovirals remaining with at least 1 but no more than 2 remaining fully active antiretrovirals that can be effectively combined to form a viable new regimen. The data reported are safety events during the 8-day double-blind period.</description>
        </group>
        <group group_id="E3">
          <title>Randomized Cohort-Total</title>
          <description>This reporting group includes all participants in the Randomized Cohort. The data reported are safety events during fostemsavir dosing until the Week 48 data cut-off date.</description>
        </group>
        <group group_id="E4">
          <title>Non-randomized Cohort-fostemsavir 600 mg BID</title>
          <description>This reporting group includes HTE HIV-1 infected participants who were assigned to the Non-randomized Cohort and received fostemsavir 600 mg BID and OBT. Non-randomized Cohort participants are assigned based on their screening status of having no remaining classes of fully active antiretroviral that can combined in a new drug regimen. The data reported are safety events during fostemsavir dosing until the Week 48 data cut-off date.</description>
        </group>
        <group group_id="E5">
          <title>Total Fostemsavir</title>
          <description>This reporting group included all enrolled participants (Randomized Cohort and Non-randomized Cohort) and who received fostemsavir 600 mg during the open-label period. The data reported are safety events during fostemsavir dosing until the Week 48 data cut-off date.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="271"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="271"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="129" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Anal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Anogenital dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Inflammatory bowel disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Malabsorption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Reactive gastropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Adverse event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune reconstitution inflammatory syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="271"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E5" events="18" subjects_affected="15" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="271"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="271"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="7" subjects_affected="4" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>HIV-associated neurocognitive disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Progressive multifocal leukoencephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Anorectal cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus chorioretinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Disseminated cytomegaloviral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hepatitis B reactivation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Histoplasmosis disseminated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Meningitis coccidioides</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Meningoencephalitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pneumonia cytomegaloviral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Salmonella bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Septic rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Tuberculosis liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Arterial bypass thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Kidney rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Open fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Shunt thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood HIV RNA increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Anal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Anal cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage IV</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Oropharyngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Penile squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Mononeuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Foetal growth restriction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="207" subjects_at_risk="271"/>
                <counts group_id="E4" subjects_affected="89" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="296" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="203"/>
                <counts group_id="E3" events="79" subjects_affected="58" subjects_at_risk="271"/>
                <counts group_id="E4" events="43" subjects_affected="24" subjects_at_risk="99"/>
                <counts group_id="E5" events="122" subjects_affected="82" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="203"/>
                <counts group_id="E3" events="60" subjects_affected="40" subjects_at_risk="271"/>
                <counts group_id="E4" events="28" subjects_affected="20" subjects_at_risk="99"/>
                <counts group_id="E5" events="88" subjects_affected="60" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E3" events="44" subjects_affected="28" subjects_at_risk="271"/>
                <counts group_id="E4" events="12" subjects_affected="9" subjects_at_risk="99"/>
                <counts group_id="E5" events="56" subjects_affected="37" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E3" events="30" subjects_affected="22" subjects_at_risk="271"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E5" events="34" subjects_affected="26" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="271"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E5" events="27" subjects_affected="26" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" events="36" subjects_affected="24" subjects_at_risk="271"/>
                <counts group_id="E4" events="23" subjects_affected="16" subjects_at_risk="99"/>
                <counts group_id="E5" events="59" subjects_affected="40" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E3" events="18" subjects_affected="17" subjects_at_risk="271"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="99"/>
                <counts group_id="E5" events="34" subjects_affected="33" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="271"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="99"/>
                <counts group_id="E5" events="24" subjects_affected="23" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" events="52" subjects_affected="37" subjects_at_risk="271"/>
                <counts group_id="E4" events="17" subjects_affected="13" subjects_at_risk="99"/>
                <counts group_id="E5" events="69" subjects_affected="50" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E3" events="39" subjects_affected="27" subjects_at_risk="271"/>
                <counts group_id="E4" events="22" subjects_affected="16" subjects_at_risk="99"/>
                <counts group_id="E5" events="61" subjects_affected="43" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" events="29" subjects_affected="25" subjects_at_risk="271"/>
                <counts group_id="E4" events="15" subjects_affected="13" subjects_at_risk="99"/>
                <counts group_id="E5" events="44" subjects_affected="38" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="35" subjects_affected="28" subjects_at_risk="271"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E5" events="41" subjects_affected="33" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="24" subjects_affected="19" subjects_at_risk="271"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="99"/>
                <counts group_id="E5" events="33" subjects_affected="28" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="271"/>
                <counts group_id="E4" events="12" subjects_affected="10" subjects_at_risk="99"/>
                <counts group_id="E5" events="27" subjects_affected="23" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="271"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E5" events="26" subjects_affected="22" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="271"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E5" events="15" subjects_affected="15" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="271"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="271"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E5" events="14" subjects_affected="13" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="22" subjects_affected="20" subjects_at_risk="271"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E5" events="31" subjects_affected="28" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="271"/>
                <counts group_id="E4" events="16" subjects_affected="13" subjects_at_risk="99"/>
                <counts group_id="E5" events="33" subjects_affected="28" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="271"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E5" events="21" subjects_affected="19" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="271"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E5" events="20" subjects_affected="17" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="271"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E5" events="12" subjects_affected="11" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="203"/>
                <counts group_id="E3" events="50" subjects_affected="34" subjects_at_risk="271"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="99"/>
                <counts group_id="E5" events="62" subjects_affected="45" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="271"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E5" events="20" subjects_affected="20" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="271"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E5" events="12" subjects_affected="11" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="271"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E5" events="20" subjects_affected="19" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="271"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E5" events="20" subjects_affected="19" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="41" subjects_affected="32" subjects_at_risk="271"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="99"/>
                <counts group_id="E5" events="52" subjects_affected="42" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="15" subjects_affected="8" subjects_at_risk="271"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E5" events="21" subjects_affected="13" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="271"/>
                <counts group_id="E4" events="8" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E5" events="14" subjects_affected="11" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="271"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="370"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="15" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E5" events="20" subjects_affected="7" subjects_at_risk="370"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

